Breast cancer is often driven by overactive hormone signaling (estrogen and/or progesterone receptors; ER, PR) or amplification of growth factor response (HER2) and treated with endocrine therapy or HER2-targeted agents. This evidence concerns the gene ERBB2 and breast carcinoma.